Literature DB >> 17475450

In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria.

José-Luis Gómez-Garcés1, Juan-Ignacio Alos, Javier Tamayo.   

Abstract

OBJECTIVES: To compare the in vitro activity of linezolid with 12 other antimicrobials against 190 strains of the coryneform bacteria, including 60 strains of C. amycolatum, 30 of C. striatum, 30 of C. jeikeium, 10 of C. urealyticum, 20 of B. casei, 20 of D. hominis and 20 of T. otitidis.
METHODS: Minimum inhibitory concentrations (MICs) and time-death curves were carried out according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI).
RESULTS: Linezolid was very active against the 130 strains of the Corynebacterium species studied. Only the glycopeptides showed similar efficacy. In contrast, penicillin G, ampicillin, macrolides, lincosamides, fluoroquinolones and aminoglycosides showed generally high MICs. Among the beta-lactams, only imipenem was active against the majority of strains of C. striatum and C. amycolatum, and, approximately half of the C. jeikeium and C. urealyticum isolates. Both Dermabacter hominis and Brevibacterium casei showed marked resistance against most of the antimicrobials tested, while Turicella otitidis only showed high MICs against macrolides and clindamycin. For all of them, linezolid, vancomycin and teicoplanin proved effective. The time-death curves showed linezolid to behave as a bacteriostatic agent (approximately 90% death rate). Such activity was more accentuated for C. amycolatum and C. striatum (reduction of 1.3 and 1.7log(10)CFU/mL, respectively) than for C. jeikeium and C. urealyticum (reduction of 1.0 and 0.8log(10), respectively).
CONCLUSIONS: Our results indicate that linezolid is active against coryneform bacteria. The efficacy of linezolid is equal to or even superior to that of the glycopeptides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475450     DOI: 10.1016/j.ijantimicag.2006.11.032

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

Review 1.  A case report and literature review of Corynebacterium urealyticum infection acquired in the hospital.

Authors:  Giuseppe Famularo; Giovanni Minisola; Giulio Cesare Nicotra; Gabriella Parisi; Claudio De Simone
Journal:  Intern Emerg Med       Date:  2008-02-12       Impact factor: 3.397

Review 2.  Turicella otitidis and Corynebacterium auris: 20 years on.

Authors:  A von Graevenitz; G Funke
Journal:  Infection       Date:  2013-06-18       Impact factor: 3.553

3.  Corynebacterium jeikeium bacteraemia and pulmonary infiltrates in a patient with acute myelogenous leukaemia.

Authors:  Kota Sato; Michihiro Uchiyama
Journal:  BMJ Case Rep       Date:  2012-03-20

4.  Quantitative lipid composition of cell envelopes of Corynebacterium glutamicum elucidated through reverse micelle extraction.

Authors:  Ritu Bansal-Mutalik; Hiroshi Nikaido
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

5.  Clinical characteristics and drug susceptibility patterns of Corynebacterium species in bacteremic patients with hematological disorders.

Authors:  Masahiro Abe; Muneyoshi Kimura; Hideyuki Maruyama; Tomohisa Watari; Sho Ogura; Shinsuke Takagi; Naoyuki Uchida; Yoshihito Otsuka; Shuichi Taniguchi; Hideki Araoka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-24       Impact factor: 3.267

6.  Bacteremia caused by Corynebacterium amycolatum with a novel mutation in gyrA gene that confers high-level quinolone resistance.

Authors:  Seoyoung Yoon; Heejung Kim; Yangsoon Lee; Sinyoung Kim
Journal:  Korean J Lab Med       Date:  2011-01

Review 7.  Corynebacterium urealyticum: a comprehensive review of an understated organism.

Authors:  Nagla Salem; Lamyaa Salem; Sally Saber; Ghada Ismail; Martin H Bluth
Journal:  Infect Drug Resist       Date:  2015-05-21       Impact factor: 4.003

8.  Dermabacter hominis: a usually daptomycin-resistant gram-positive organism infrequently isolated from human clinical samples.

Authors:  I Fernández-Natal; J A Sáez-Nieto; M J Medina-Pascual; A Albersmeier; S Valdezate; J M Guerra-Laso; H Rodríguez; T Marrodán; T Parras; A Tauch; F Soriano
Journal:  New Microbes New Infect       Date:  2014-01-13

9.  Susceptibility to Aminoglycosides and Distribution of aph and aac(3)-XI Genes among Corynebacterium striatum Clinical Isolates.

Authors:  Jesús Navas; Marta Fernández-Martínez; Carlos Salas; María Eliecer Cano; Luis Martínez-Martínez
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

10.  Draft Genome Sequence of the Multidrug-Resistant Clinical Isolate Dermabacter hominis 1368.

Authors:  Andreas Albersmeier; Christina Bomholt; Alina Glaub; Christian Rückert; Francisco Soriano; Isabel Fernández-Natal; Andreas Tauch
Journal:  Genome Announc       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.